+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Type 2 Diabetes Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 5910862
The type 2 diabetes market was valued at USD 35.00 Billion in 2024, driven by the rising prevalence of type 2 diabetes across the 8 major markets. The market is expected to grow at a CAGR of 8.40% during the forecast period of 2025-2034, with the values likely to rise from USD 78.41 Billion by 2034 .

Type 2 Diabetes Market Overview

Type 2 diabetes refers to a chronic condition that affects the processing of blood sugar (glucose) in the body. People with type 2 diabetes often experience high blood sugar levels, a relative lack of insulin, and insulin resistance. The rising burden of type 2 diabetes is driving the demand for diabetes management solutions. Further, advancements in treatment options including the development of GLP-1 receptor agonists and insulin delivery technologies are poised to favor market growth. Moreover, the rise in public health campaigns and screening programs along with the growth in digital health solutions to advance diabetes care are anticipated to influence the market dynamics positively.

Type 2 Diabetes Market Growth Drivers

Increasing Prevalence of Type 2 Diabetes Drives Market Growth

The prevalence of diabetes is increasing rapidly across the globe, especially in low- and middle-income countries. Recent data suggests that 95% of people living with diabetes have type 2 diabetes, which can seriously damage the blood vessels and nerves in the body. It is estimated that 643 million people will have diabetes by 2030, which is further projected to increase to 783 million by 2045. Thus, the rising cases of type 2 diabetes are expected to contribute significantly to the market growth in the forecast period.

Type 2 Diabetes Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Strategic Mergers and Acquisitions to Affect the Market Landscape Significantly

Prominent market players are stepping forward to enhance their diabetes care portfolio propelled by the surge in the demand for diabetes medications. For instance, in March 2023, Sanofi announced the acquisition of Provention Bio, a United States-based biopharmaceutical company, in order to expand its diabetic care presence and reinforce its market position in the diabetes treatment space. Such strategic merger and acquisition events are expected to impact market growth.

Increased R&D Initiatives Poised to Elevate Type 2 Diabetes Market Value

The ongoing research and development directed at developing improved drugs with higher efficacy and fewer side effects is likely to aid market growth. For example, Fractyl Health, a Massachusetts-based biotech company, is working towards developing a one-time gene therapy intended to lower body weight as well as blood sugar levels. The drug is set to mimic a human hormone called GLP-1 that is released in the gut in response to eating. Such research initiatives are poised to favor market expansion in the coming years.

Surge in Regulatory Approvals to Augment the Type 2 Diabetes Market Demand

In August 2024, Insulet Corporation, a medical device company specializing in insulin delivery systems, announced the U.S. Food and Drug Administration (FDA) approval of its patient-centric technology Omnipod 5 Automated Insulin Delivery System for the management of type 2 diabetes. The rise in regulatory approvals of innovative drugs and devices for type 2 diabetes is projected to amplify the market demand in the forecast period.

Growing Awareness Campaigns to Boost Type 2 Diabetes Market Size

To control and minimize the adverse effects of the disease, prominent organizations like the World Health Organization (WHO) have been initiating significant campaigns. WHO has launched a new initiative called BeatDiabetes in the Indian region, aimed at increasing awareness and promoting a healthy lifestyle. Such awareness campaigns are set to bolster the market demand for effective treatments.

Type 2 Diabetes Market Segmentation

Global Type 2 Diabetes Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type

  • Oral
  • Biguanides
  • Meglitinides
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • SGLT-2 Inhibitors
  • Sulfonylureas
  • Others
  • Injectable
  • Insulin
  • GLP-1 Receptor Agonists
  • Others
  • Others

Market Breakup by Drug Delivery Method

  • Oral
  • Injections
  • Pen Devices
  • Insulin Devices
  • Others

Market Breakup by End User

  • Hospitals and Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Type 2 Diabetes Market Share

Market Segmentation Based on Drug Delivery Method is Anticipated to Witness Substantial Growth

The market breakup by drug delivery method includes oral, injections, pen devices, insulin devices, and others. Oral medications are most commonly used to manage type 2 diabetes, especially for patients who are in the early stages of the disease. Popular drugs like metformin and sulfonylureas are available in oral forms. Oral medications are easy to administer and are also a preferred option for patients who are hesitant about injections.

Type 2 Diabetes Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to a well-established infrastructure and the presence of major healthcare companies that are actively working to provide novel solutions. Further, significant funding to advance type 2 diabetes treatments is also expected the market growth in the region. For instance, in August 2023, the National Institutes of Health offered USD 3.5 million to conduct a large-scale clinical trial testing that can prove pivotal for new drug development.

Leading Players in the Type 2 Diabetes Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows

Novo Nordisk A/S

Danish multinational pharmaceutical Novo Nordisk is one of the leading players in the market, boasting production facilities in nine countries. The global healthcare company is actively focused on advancing treatment for type 2 diabetes from injections to tablets. Novo Nordisk has also demonstrated that a synthetic version of the glucagon-like peptide-1 (GLP-1) hormone, which lowers glucose levels in the blood, can be taken in the form of a tablet.

Sanofi SA

Headquartered in Paris, France, this multinational pharmaceutical and healthcare company has a prominent presence in the market. In April 2024, Sanofi India launched Soliqua, a once-daily diabetes injectable drug in India at the cost of INR 1850 per pen.

Pfizer Inc

Pfizer, based in New York, United States, significantly contributes to the development of the market through its extensive research capabilities and robust market presence. The company is engaged in the clinical development of its oral GLP-1-RA candidate danuglipron for the treatment of type 2 diabetes mellitus.

Merck & Co.

American multinational pharma Merck & Co. is a major market player and is known for its strong portfolio of prescription medicines, vaccines, and biologic therapies, among others. The company's 'See it. Slow it. Stop it.' campaign educates the public about the warning signs of type 2 diabetes and encourages people at risk to make simple lifestyle changes.

Other key players in the market include Boehringer Ingelheim International GmbH, Eli Lilly and Company, Abbott Laboratories, AstraZeneca plc, Bayer AG, and GSK plc., among others.

Key Questions Answered in the Type 2 Diabetes Market Report

  • What was the type 2 diabetes market value in 2024?
  • What is the type 2 diabetes market forecast outlook for 2025-2034?
  • What are the regional markets covered in the report?
  • What is market segmentation based on drug type?
  • What is the market breakup based on drug delivery methods?
  • Who are the major end users in the market?
  • What are the major factors aiding the type 2 diabetes market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • How do the prevalence and incidence of type 2 diabetes affect the market landscape?
  • What are the major type 2 diabetes market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which drug type will dominate the market share?
  • Which drug delivery method is expected to have a high market value in the coming years?
  • Which end user is projected to contribute to the highest market growth?
  • Who are the key players involved in the type 2 diabetes market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Type 2 Diabetes Market Overview: 8 Major Markets
3.1 Type 2 Diabetes Market Historical Value (2018-2024)
3.2 Type 2 Diabetes Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Type 2 Diabetes: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Type 2 Diabetes Market Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 United States
7.1.1.2 United Kingdom
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 United States
7.1.2.2 United Kingdom
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 United States
7.1.3.2 United Kingdom
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Type 2 Diabetes Market Landscape: 8 Major Markets*
8.1 Type 2 Diabetes Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Type 2 Diabetes Market: Product Landscape
8.2.1 Analysis by Drug Type
8.2.2 Analysis by Drug Delivery Method
9 Type 2 Diabetes Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Type 2 Diabetes Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Type 2 Diabetes Market Segmentation: 8 Major Markets
12.1 Type 2 Diabetes Market (2018-2034) by Drug Type
12.1.1 Market Overview
12.1.2 Oral
12.1.2.1 Biguanides
12.1.2.2 Meglitinides
12.1.2.3 Thiazolidinediones
12.1.2.4 Alpha-Glucosidase Inhibitors
12.1.2.5 SGLT-2 Inhibitors
12.1.2.6 Sulfonylureas
12.1.2.7 Others
12.1.3 Injectable
12.1.3.1 Insulin
12.1.3.2 GLP-1 Receptor Agonists
12.1.3.3 Others
12.1.4 Others
12.2 Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Injections
12.2.4 Pen Devices
12.2.5 Others
12.3 Type 2 Diabetes Market (2018-2034) by End User
12.3.1 Market Overview
12.3.2 Hospitals and Clinics
12.3.3 Retail Pharmacies
12.3.4 Online Pharmacies
12.3.5 Others
12.4 Type 2 Diabetes Market (2018-2034) by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Type 2 Diabetes Market (218-2034)
13.1 United States Type 2 Diabetes Market Historical Value (2018-2024)
13.2 United States Type 2 Diabetes Market Forecast Value (2025-2034)
13.3 United States Type 2 Diabetes Market (2018-2034) by Drug Type
13.3.1 Market Overview
13.3.2 Oral
13.3.2.1 Biguanides
13.3.2.2 Meglitinides
13.3.2.3 Thiazolidinediones
13.3.2.4 Alpha-Glucosidase Inhibitors
13.3.2.5 SGLT-2 Inhibitors
13.3.2.6 Sulfonylureas
13.3.2.7 Others
13.3.3 Injectable
13.3.3.1 Insulin
13.3.3.2 GLP-1 Receptor Agonists
13.3.3.3 Others
13.3.4 Others
13.4 United States Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Injections
13.4.4 Pen Devices
13.4.5 Others
13.5 United States Type 2 Diabetes Market (2018-2034) by End User
13.5.1 Market Overview
13.5.2 Hospitals and Clinics
13.5.3 Retail Pharmacies
13.5.4 Online Pharmacies
13.5.5 Others
14 EU-4 and United Kingdom Type 2 Diabetes Market (218-2034)
14.1 EU-4 and United Kingdom Type 2 Diabetes Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Type 2 Diabetes Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Type 2 Diabetes Market (2018-2034) by Drug Type
14.3.1 Market Overview
14.3.2 Oral
14.3.2.1 Biguanides
14.3.2.2 Meglitinides
14.3.2.3 Thiazolidinediones
14.3.2.4 Alpha-Glucosidase Inhibitors
14.3.2.5 SGLT-2 Inhibitors
14.3.2.6 Sulfonylureas
14.3.2.7 Others
14.3.3 Injectable
14.3.3.1 Insulin
14.3.3.2 GLP-1 Receptor Agonists
14.3.3.3 Others
14.3.4 Others
14.4 EU-4 and United Kingdom Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Injections
14.4.4 Pen Devices
14.4.5 Others
14.5 EU-4 and United Kingdom Type 2 Diabetes Market (2018-2034) by End User
14.5.1 Market Overview
14.5.2 Hospitals and Clinics
14.5.3 Retail Pharmacies
14.5.4 Online Pharmacies
14.5.5 Others
15 Japan Type 2 Diabetes Market (218-2034)
15.1 Japan Type 2 Diabetes Market Historical Value (2018-2024)
15.2 Japan Type 2 Diabetes Market Forecast Value (2025-2034)
15.3 Japan Type 2 Diabetes Market (2018-2034) by Drug Type
15.3.1 Market Overview
15.3.2 Oral
15.3.2.1 Biguanides
15.3.2.2 Meglitinides
15.3.2.3 Thiazolidinediones
15.3.2.4 Alpha-Glucosidase Inhibitors
15.3.2.5 SGLT-2 Inhibitors
15.3.2.6 Sulfonylureas
15.3.2.7 Others
15.3.3 Injectable
15.3.3.1 Insulin
15.3.3.2 GLP-1 Receptor Agonists
15.3.3.3 Others
15.3.4 Others
15.4 Japan Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Injections
15.4.4 Pen Devices
15.4.5 Others
15.5 Japan Type 2 Diabetes Market (2018-2034) by End User
15.5.1 Market Overview
15.5.2 Hospitals and Clinics
15.5.3 Retail Pharmacies
15.5.4 Online Pharmacies
15.5.5 Others
16 India Type 2 Diabetes Market (218-2034)
16.1 India Type 2 Diabetes Market Historical Value (2018-2024)
16.2 India Type 2 Diabetes Market Forecast Value (2025-2034)
16.3 India Type 2 Diabetes Market (2018-2034) by Drug Type
16.3.1 Market Overview
16.3.2 Oral
16.3.2.1 Biguanides
16.3.2.2 Meglitinides
16.3.2.3 Thiazolidinediones
16.3.2.4 Alpha-Glucosidase Inhibitors
16.3.2.5 SGLT-2 Inhibitors
16.3.2.6 Sulfonylureas
16.3.2.7 Others
16.3.3 Injectable
16.3.3.1 Insulin
16.3.3.2 GLP-1 Receptor Agonists
16.3.3.3 Others
16.3.4 Others
16.4 India Type 2 Diabetes Market (2018-2034) by Drug Delivery Method
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Injections
16.4.4 Pen Devices
16.4.5 Others
16.5 India Type 2 Diabetes Market (2018-2034) by End User
16.5.1 Market Overview
16.5.2 Hospitals and Clinics
16.5.3 Retail Pharmacies
16.5.4 Online Pharmacies
16.5.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Drug Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Novo Nordisk A/S
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Company News and Developments
23.2.5 Certifications
23.3 Sanofi SA
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Company News and Developments
23.3.5 Certifications
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Company News and Developments
23.4.5 Certifications
23.5 Merck & Co.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Company News and Developments
23.5.5 Certifications
23.6 Boehringer Ingelheim International GmbH
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Company News and Developments
23.6.5 Certifications
23.7 Eli Lilly and Company
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Company News and Developments
23.7.5 Certifications
23.8 Abbott Laboratories
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Company News and Developments
23.8.5 Certifications
23.9 AstraZeneca plc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Company News and Developments
23.9.5 Certifications
23.10 Bayer AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Company News and Developments
23.10.5 Certifications
23.11 GSK plc
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Company News and Developments
23.11.5 Certifications
24 Type 2 Diabetes Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

Companies Mentioned

  • Novo Nordisk A/S
  • Sanofi SA
  • Pfizer Inc.
  • Merck & Co.

Table Information